Teva acquires Ivax
This article was originally published in The Tan Sheet
Executive Summary
Teva has completed the acquisition of generics firm Ivax Jan. 26, the Israeli firm announces in a same-day release. The deal increases Teva's OTC distribution and private label OTC portfolio (1"The Tan Sheet" Aug. 1, 2005, p. 11). To preserve competition, FTC requires that Teva divest all of the rights and assets related to 15 of the firms' prescription generics. The rights and assets to be divested will be divided between Barr Pharmaceuticals and Par Pharmaceuticals. Teva and Ivax are required to provide transitional services to Barr and Par until the firms receive FDA approval to manufacture the drugs themselves. The order will be open to public comment until Feb. 21, 2006. FTC will decide whether to make the order final following the close of the public comment period...
You may also be interested in...
FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy
FDA is assessing its next step following an appeals court ruling confirming that the agency's position on delisting patents is inconsistent with Hatch/Waxman
Teva/Ivax finalized
FTC has approved the final consent order related to Teva Pharmaceuticals' acquisition of fellow generics firm Ivax following an open public comment period, the commission announces March 7. The acquisition was completed Jan. 26 (1"The Tan Sheet" Jan. 30, 2006, In Brief)...
Teva Broadens Private Label OTC Offerings With Ivax Acquisition
Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio